Atopic Dermatitis Market H2 2015 Pipeline Review

This research provides comprehensive information on the therapeutic development for Atopic Dermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Atopic Dermatitis and special features on late-stage and discontinued projects.

The research enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Inquire before buying this research at: .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The research is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the research undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope for this research:

·         The report provides a snapshot of the global therapeutic landscape of Atopic Dermatitis

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Atopic Dermatitis and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Atopic Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

·         Coverage of the Atopic Dermatitis pipeline on the basis of target, MoA, route of administration and molecule type

Companies mentioned: Abeome Corporation, AlbireoPharma, Almirall, S.A., Amgen Inc., Amorepacific Corporation, Anacor Pharmaceuticals, Inc., AnaMar AB, AnaptysBio, Inc., AnGes MG, Inc., Aquinox Pharmaceuticals Inc., arGEN-X BV, Blueberry Therapeutics Ltd, Brickell Biotech, Inc., Celgene Corporation, ChemoCentryx, Inc., ChironWells GmbH, Chugai Pharmaceutical Co., Ltd., Creabilis SA, Delenex Therapeutics AG, Dermira Inc., Eisai Co., Ltd., F. Hoffmann-La Roche Ltd., Foamix Pharmaceuticals Ltd., Fountain Biopharma Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Grupo Ferrer Internacional, S.A., HanAll Biopharma Co., Ltd., Herantis Pharma Plc, IMMD Inc., Immune Pharmaceuticals Inc., Inflamalps SA, Japan Tobacco Inc., Johnson & Johnson, LegoChem Biosciences, Inc, LEO Pharma A/S, Madam Therapeutics B.V., MedImmune, LLC, Mitsubishi Tanabe Pharma Corporation, NeoPharm Co., Ltd., Novartis AG, Nuvo Research Inc., Otsuka Holdings Co., Ltd., Oxagen Limited, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Provectus Biopharmaceuticals, Inc., R-Tech Ueno, Ltd., Regeneron Pharmaceuticals, Inc., Signum Dermalogix, Inc, Spherium Biomed S.L., sterna biologicals Gmbh & Co KG, Sun Pharma Advanced Research Company Ltd., Vicore Pharma AB, Vitae Pharmaceuticals, Inc., VivaCell Biotechnology Espana S.L., Welichem Biotech Inc., Xencor, Inc., Yungjin Pharm. Co., Ltd. and Ziarco Pharma Ltd

Complete research on H2 Pipeline Review of ‘Atopic Dermatitis’ spread across 340 pages at .

Reasons to buy this research:

·         Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

·         Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

·         Develop strategic initiatives by understanding the focus areas of leading companies

·         Identify and understand important and diverse types of therapeutics under development for Atopic Dermatitis

·         Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

·         Devise corrective measures for pipeline projects by understanding Atopic Dermatitis pipeline depth and focus of Indication therapeutics

·         Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline